Johnson & Johnson and Mayo Clinic both invested in DayTwo, the developer of a microbiome health management app, with the latter set to expand its research partnership with the startup.
DayTwo, the Israel-based creator of a microbiome health management app, raised $12m on Tuesday in a series A round featuring healthcare group Johnson & Johnson’s corporate venturing unit, Johnson & Johnson Innovation – JJDC.
Medical research firm Mayo Clinic also invested in the round, as did venture capital firm Seventure Partners’ Health for Life Capital fund, DayTwo co-founder Marius Nacht and undisclosed private investors.
DayTwo has developed an app that measures a user’s post-meal blood sugar and uses machine learning…
